The value of patient-based cell models and brain organoids in unpicking the complexities of neurodegenerative diseases is again highlighted in new research showing how mutations that cause a rare subtype of Parkinson's disease operate at a cellular level.
Using stem cells derived from members of families carrying mutations in the PARK7 gene that are linked to an early onset form of Parkinson's disease, the researchers at the University of Luxembourg directly observed that these defects disrupt exon splicing.
That interferes with the activity of a small RNA called U1, reducing production of the DJ-1 protein (also called Parkinsonism associated deglycase), which among other functions, is involved in mitochondrial regulation. The researchers found that mitochondria in the patient-derived cell models malfunctioned as a result.
Based on this insight, Ibrahim Boussaad and colleagues designed a combination therapy that repaired these aberrations, halting the death of dopaminergic neurons in brain organoids.
The researchers say the study, published in the latest issue of Science Translational Medicine, provides a foundation to develop therapies that could help correct the genetic cause of some forms of Parkinson's disease.
"When PARK7 was first discovered it was described as causing the substitution of an amino acid. It's only when we got patient material we could see it's not substitution. We saw it was a problem with splicing," Boussaad told BioWorld Science.
There are more than 25 PARK7 gene mutations that are implicated in Parkinson's disease. However, it previously was unclear how loss of functional DJ-1 protein causes the neurodegenerative disease, with some studies suggesting PARK7 mutations disrupt the protein's chaperone function, leading to a toxic buildup of misfolded proteins, while others suggest PARK7 mutations impair DJ-1's ability to protect cells from oxidative stress.
Boussaad said the researchers were aiming to pinpoint specific defects in the mutant DJ-1 protein generated by the patient cell models. Instead, they found there was little or no trace of the protein at all.
The possibility that the protein was unstable and had degenerated was excluded by blocking degradation pathways to show there were no metabolites of the protein.
"So we took a step back and started to look upstream. We could detect [PARK7] RNA, but it was shorter," said Boussaad. "On sequencing the products, we saw an entire section of RNA was missing."
Luckily, one of the donors was heterozygous for PARK7, and in this case it was possible to detect both normal length and shorter RNA, helping to confirm that mis-splicing was blocking DJ-1 production.
The researchers showed it was possible to correct the defective exon skipping using genetically engineered U1-snRNA (small nuclear RNA). That corrected DJ-1 expression in neuronal precursor cells and differentiated neurons.
They also demonstrated that combination treatment with the small molecules RECTAS (rectifier of aberrant splicing) and phenylbutyric acid repaired the splicing defects, restoring DJ-1 production, correcting mitochondrial function and preventing loss of dopaminergic cells in mutant PARK7 brain organoids.
Looking at sequence databases, the researchers found that similar splicing mutations appeared more frequently in the genomic data from 2,710 patients with the common sporadic form of Parkinson's disease, than in data from 5,713 controls, pointing to a wider significance of the current study.
With the literature suggesting that as many as a third of all disease-causing mutations exert their effects through faulty exon splicing, the findings could also have relevance to other conditions.
The direct observation of the cellular-level impact of one of these mutations and the possibility of therapeutic intervention, should lead to greater focus in this area, Boussaad said. "There are a few other such mutations known and described, but they have not got the attention they should have in the field of neurodegenerative diseases."
As a next step, the researchers plan to further develop the combination treatment. "We are going into animal models to see how potent it is in entire organisms. We also want to look at availability in the brain and if compounds have the ability to cross the blood-brain barrier," said Boussaad. "And of course, the other direction will be to further explore the abundance of exon splicing mutations in Parkinson's disease."
It is becoming increasingly clear that although patients with Parkinson's present with the same motor symptoms, there are subtypes of the disease which have different etiologies. "To advance treatment, we have to stratify. We have to investigate for each patient, why they have this disease," Boussaad said.
That could form the basis of customized treatments. "If we can identify patients with exon splicing mutations it will have positive benefits. If they can be corrected, it will restore the protein and be neuroprotective, rather than treating the symptoms," said Boussaad. "It could have a significant impact." (Boussaad, I. et al. Sci Transl Med 2020, 12: eaau3960).
Read the original post:
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% - Yahoo Finance - May 7th, 2021
- Diabetes and muscle weakness: Why the link? - Medical News Today - May 7th, 2021
- A Peek At The Hand Of Cell, Gene And RNA Therapies - In Vivo - May 7th, 2021
- Jasper Therapeutics and Amplit - GuruFocus.com - May 7th, 2021
- The Stem Cell Chronicles: Dr. Beau Hightower On Incredible Health Benefits of SCT - Maxim - May 7th, 2021
- Kill Cancer with Fasting - Greater Kashmir - May 7th, 2021
- Are labgrown embryos and human hybrids ethical? - Big Think - May 7th, 2021
- HealthLynked Releases Recent "Future of Healthcare" Summit in Virtual Format - PRNewswire - May 7th, 2021
- Stem cell therapy for COPD: Cost, effectiveness, and more - Medical News Today - April 30th, 2021
- The central role of DNA damage in the ageing process - Nature.com - April 30th, 2021
- Examine Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 | CAGR 8.5% - WhaTech - April 30th, 2021
- Matcha vs. green tea: Differences and benefits - Medical News Today - April 30th, 2021
- FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for Previously Untreated Metastatic Bladder Cancer... - April 30th, 2021
- Stem Cell Therapy Market To Register Phenomenal Growth in the Period of 2027 Valley Bugler Newspaper - Valley Bugler Newspaper - April 30th, 2021
- FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for PD-L1-Positive, Metastatic Triple-Negative... - April 28th, 2021
- Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001 for... - April 28th, 2021
- Synthetic Stem Cells Comprehensive Analysis on Global Market Report by Company, by Dynamics, by Region, by Type, by Application and by COVID-19... - April 26th, 2021
- Labgrown embryos and humanmonkey hybrids: Medical marvels or ethical missteps? - The Conversation US - April 26th, 2021
- Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health - GlobeNewswire - April 22nd, 2021
- How UFC Legends, Super Bowl Champions And More Use Stem Cell Therapy To Improve Their Quality of Life - Maxim - April 22nd, 2021
- Scientists Just Bioprinted a Pancreas That Could End Diabetes - Interesting Engineering - April 22nd, 2021
- Kadmon Announces Publication of Phase 2a Clinical Trial Results of Belumosudil for cGVHD in the Journal of Clinical Oncology - BioSpace - April 22nd, 2021
- bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations - Business Wire - April 22nd, 2021
- Stem Cell Therapy Market with Impact of COVID-19, Top Companies, Emerging Trends, Demand Analysis, Future Opportunity Outlook 2027 The Courier - The... - April 20th, 2021
- As scientists move closer to making part human, part animal organisms, what are the concerns? - The Conversation AU - April 20th, 2021
- Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell... - April 20th, 2021
- bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations - StreetInsider.com - April 20th, 2021
- Shawn Vestal: A mother's journey from Honduras to Spokane 'I'm going to carry my girl' - The Spokesman-Review - April 18th, 2021
- Agenus Doses First Cancer Patient with iNKT Cell Therapy - GlobeNewswire - April 18th, 2021
- In race against COVID variants, scientists and doctors agree: The time to get vaccinated is now - Greeley Tribune - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- Daily briefing: A graphical guide to vaccine benefits and risks - Nature.com - April 14th, 2021
- Stem Cell Therapy Market To Register Phenomenal Growth in the Period of 2027 The Courier - The Courier - April 14th, 2021
- Collaboration Furthers Understanding of Immune Cell Development | Newsroom - UC Merced University News - April 14th, 2021
- Biotech EryPharm Announces a Revolutionary Technological Breakthrough in the Large- Scale Manufacturing of Red Blood Cells - Business Wire - April 14th, 2021
- New Research Models Offer Promise for Understanding the Human Brain and Finding Pathways to Therapies, But Also Raise Profound Ethical Questions - The... - April 14th, 2021
- The Beljanski Foundation Launches New Website Raising Awareness on Scientific Research for Cancer and Other Chronic Diseases - PRNewswire - April 14th, 2021
- Novel Tx Helped Man With Recurrent Brain Tumor - MedPage Today - April 14th, 2021
- [Full text] Armored Car T-Cells: T-Cell Cancer Immunotherapy | BTT - Dove Medical Press - April 14th, 2021
- Insights on the Gene Therapy Cell Culture Media Global Market to 2027 - Growth in Awareness Regarding Gene Therapy is Driving Growth - Yahoo Finance - April 10th, 2021
- Dynamic Stem Cell Therapy Announces The Launch of Its Advanced Stem Cell Treatment For Knee Injury - Press Release - Digital Journal - April 10th, 2021
- Diet and the immune system: What is the link? - Medical News Today - April 10th, 2021
- New stem cell therapy shows promise to prevent diabetes-related amputations - News-Medical.Net - April 8th, 2021
- Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model - StreetInsider.com - April 8th, 2021
- Diabetes drug could prevent brain damage in children receiving radiation for tumours: U of T study - News@UofT - April 8th, 2021
- Automated and Closed Cell Therapy Processing Systems Markets, 2030 - PRNewswire - April 8th, 2021
- Stem cell transplants offer long-term benefits for pediatric cancer patients receiving immunotherapy - News-Medical.Net - April 1st, 2021
- Bio-Techne has announced launch of Cultrex Ultimatrix BME to support organoid and pluripotent stem cell cultures - SelectScience - April 1st, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 1st, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 1st, 2021
- Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End... - April 1st, 2021
- The role of antirheumatics in patients with COVID-19 - The Lancet - April 1st, 2021
- Cultured Meat: What to Know - WebMD - March 30th, 2021
- Hydrogel used to revert cancer cells back to cancer stem cells - Drug Target Review - March 30th, 2021
- The epigenetics of aging: What the body's hands of time tell us - National Institute on Aging - March 30th, 2021
- Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of... - March 30th, 2021
- PolarityTE Reports Fourth Quarter and Fiscal Year 2020 Results - Argus Press - March 30th, 2021
- Phase 3 Trial of Stem Cell Therapy NeuroNata-R Likely to Expand to US - ALS News Today - March 26th, 2021
- [Full text] Review of Chimeric Antigen Receptor T-cell Therapy | OTT - Dove Medical Press - March 26th, 2021
- Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC for Treatment of ICU COVID-19 Patients - StreetInsider.com - March 26th, 2021
- FLASH Radiotherapy: An (r)evolution in cancer treatment - Open Access Government - March 26th, 2021
- Money on the Move: March 17-23 - BioSpace - March 26th, 2021
- Stanford Researchers Find Culprit In Muscle Aging And How To Knock It Down - Bio-IT World - March 22nd, 2021
- Pivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning - Business Wire - March 22nd, 2021
- Cell Harvesting System Market Report 2021 : Rising Impressive Business Opportunities Analysis with Top Countries Data Forecast By 2027 The Courier -... - March 22nd, 2021
- 10 Weird but Effective Anti-Aging Ingredients for Your Skin - Real Simple - March 22nd, 2021
- UK to test existing drugs as treatment for MS in world-first trial - The Guardian - March 22nd, 2021
- The Costly, Painful, Lonely Burden of Care - The New York Times - March 17th, 2021
- Taking nutrition from personalization to precision | AgriLife Today - AgriLife Today - March 17th, 2021
- When will cell-cultured meat reach price parity with conventional meat? - FoodNavigator-USA.com - March 17th, 2021
- Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 - PRNewswire - March 13th, 2021
- Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the... - March 13th, 2021
- Bone Marrow-Derived Stem Cells (BMSCS) Market To Witness Relatively Significant Growth During Forecast to 2027 The Courier - The Courier - March 9th, 2021
- Stem Cells, The Good, The Bad and The Ugly - The Miami Project - March 7th, 2021
- 5 Proven Advantages and Disadvantages of Stem Cell ... - March 7th, 2021
- Cell Banking Outsourcing Market 2021 By Size, Key Players Profile, In-Depth Qualitative Insights, Future Plans, COVID-19 Market Outlook, Industry... - March 5th, 2021
- Dynamic Stem Cell Therapy Offers Regenerative Medicine - Las Vegas Review-Journal - March 5th, 2021
- Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I - PharmiWeb.com - March 5th, 2021
- AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis - Business Wire - March 5th, 2021
- 5 Health Benefits of Artichokes, According to a Nutritionist - Health.com - March 5th, 2021